Workflow
接好孕
icon
Search documents
水滴公司(WDH.US)2025年Q1营收7.54亿元 连续13个季度实现盈利
智通财经网· 2025-06-05 10:18
Core Insights - Waterdrop Inc. reported a net revenue of 754 million yuan for Q1 2025, representing a year-on-year growth of 7% [1] - The company achieved a net profit attributable to shareholders of 108 million yuan, marking a 34.2% increase year-on-year, and has maintained profitability for 13 consecutive quarters [1] - Operating expenses as a percentage of revenue decreased by 6.1 percentage points to 40.3% [1] Financial Performance - Insurance-related revenue reached 658 million yuan, up 8.4% year-on-year, with operating profit at 151 million yuan [1] - The first-year scale premium for the insurance business grew by 19.3% to 2.092 billion yuan [1] - Short-term insurance first-year scale premium increased by 30.1% [1] Product Development - The company upgraded its exclusive maternal and infant insurance product "Jie Hao Yun" to version 5.0, adding various disease coverages and introducing a medication subsidy [2] - Waterdrop launched the "All Insurance" million medical insurance, the first in the industry to offer guaranteed renewal for five years without health declarations, targeting chronic and sub-healthy individuals [2] AI and Technology Integration - Waterdrop has applied for 51 patents related to large model capabilities as of the end of Q1 [2] - AI applications have significantly improved efficiency across various business segments, with the "AI Quality Inspection Assistant" enhancing quality management efficiency by 83% [2] - The "Waterdrop AI Insurance Expert" contributed over 2 million yuan in premium assistance in a single month [2] Social Impact and Other Business Segments - Waterdrop Fund has facilitated donations of 68.8 billion yuan to approximately 3.47 million patients since its inception, with a Q1 operating loss of about 30.2 million yuan [3] - The digital clinical trial solution business generated a net revenue of 23 million yuan, reflecting an 11.5% year-on-year growth, with partnerships reaching 185 pharmaceutical and CRO companies [3]